Therapeutic efficacy of latoconazole in formulations of clinical use on experimental dermatophytosis in guinea pigs.
Therapeutic efficacy of clinical dosage forms of latoconazole (NND-318, CAS 101530-10-3), related compound of ketene dithioacetals with an imidazole ring, was examined on two experimental tinea models: a recently developed tinea pedis model and a conventional tinea corporis model in guinea pigs. The efficacy of the dosage forms was estimated on the basis of the rate of fungus-positive skin cultures and/or the score of skin lesions, and was compared to the other antifungal agents, bifonazole, clotrimazole and tolnaftate. While these reference agents exhibited curative effect on the tinea corporis model, the tinea pedis model was considerably resistant to the therapeutic treatment of the agents. The cream preparation and solution of lactoconazole at concentrations of more than 0.25% were highly effective in either tinea models, and at concentrations of more than 1%, lactoconazole achieved complete mycological cure. These results suggest that 1% of lactonazole is an optimal concentration for clinical use.
Oka
H
H
Pharmaceutical Research Institute, Nihon Nohyaku Co., Ltd., Osaka, Japan.
Niwano
Y
Y
Ohmi
T
T
Tanaka
T
T
Uchida
M
M
Yamaguchi
H
H
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D006168:Guinea Pigs; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009824:Ointments; D014005:Tinea / Q000188:drug therapy* / Q000382:microbiology; D014008:Tinea Pedis / Q000188:drug therapy / Q000382:microbiology
D000935:Antifungal Agents; D006571:Heterocyclic Compounds; D007093:Imidazoles; D009824:Ointments; C072774:latoconazole